Elan Unit’s Acquisition Brings Diversification, Cash Flow, To Alkermes
Executive Summary
Alkermes Inc's acquisition of Elan Corp.'s Elan Drug Technology, announced May 9, more than doubles the revenues of one of the biopharma industry's most successful reformulation companies, and provides it with additional cash flow it needs to pursue a slate of innovative compounds it is developing.
You may also be interested in...
With Alkermes’ Transition Well Under Way, Commercial Expansion Is Next
As Alkermes advances its proprietary pipeline, the company is beginning to build its commercial organization ahead of what will be the launch of its first wholly owned drug since it took the marketing reins with Vivitrol in 2008.
Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid
Perrigo is using Elan’s beneficial tax rates to launch its international expansion and the royalty stream from Tysabri to help fund those M&A endeavors, but is not dramatically changing its OTC focus.
Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid
Perrigo is using Elan’s beneficial tax rates to launch its international expansion and the royalty stream from Tysabri to help fund those M&A endeavors, but is not dramatically changing its OTC focus.